3Herbst RS;Maddox AM;Rothenberg ML.Selective oral epidermal growth factor receptor tyroslne kinase inhibitor ZDl839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors:results of a phase Ⅰ trial[J],2002(18).
4Herbst BS.Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients[J],2003(01).
5Cella D.Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy lung scale,2003(01).
3Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-call lung cancer. J Clin Oncol, 2003, 21 :2237 -2246.
4Herbst RS, Maddox AM, Rothenherg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase Ⅰ trial. J Clin Oncol, 2002, 20:3815-3825.
5Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839(Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res, 2001, 7 : 1459-1465.
6Ryan PD, Chabner BA. On receptor inhibitors and chemotherapy.Clin Cancer Res, 2000, 6:4607-4609.
7Nicholson RI, Gec JM, Harper ME. EGFR and cancer prognosis.Eur J Cancer, 2001, 37(Suppl 4) :S9-15.
8Schmidt M, Maurer-gebhard M, Groner B, et al. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors.Oncogene, 1999, 18 : 1711-1721.
9Kris MG, Natale BB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290:2149-2158.
10Tamura K, Fukuoka M. Gefitinib in non-small cell lung cancer.Expert Opin Pharmacother, 2005, 6:985-993.
